Hanon Systems Develops World’s First 4th Generation Heat Pump System for Electric Vehicles By Investing.com Read more
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease Read more
3 in 4 Gen Zers are interested in vocational training as uncertainty and AI shape the minds of the next ‘toolbelt generation’ Read more